Search
Close this search box.
Subscriber Log In
Search
Resources

Resource Centre

Looking for the latest from the Evaluate team? Below you’ll find our latest blogs, reports, webinars and more. Whether you’re looking for detailed analysis of the state of the biopharma market, or a quick primer on a particular topic, you’re in the right place.

Most Recent

Widget Debug Data (turned on by setting in widget advanced section)
Array
(
    [ uc_serial] => 43654
    [ uc_id] => uc_post_grid_elementor_59eb565
    [ uc_assets_url] => https://www.evaluate.com/wp-content/uploads/ac_assets/uc_post_grid_style_one/
    [ uc_url_home] => https://www.evaluate.com
    [ uc_url_blog] => https://www.evaluate.com/?post_type=post
    [ uc_lang] => en
    [ uc_inside_editor] => no
    [ uc_admin_user] => no
    [ image_link_type] => Array
        (
            [image_link_type] => 
            [image_link_type_link_type] => post
            [image_link_type_meta_field] => 
        )

    [ uc_dynamic_popup_class] => 
    [ sequence_entrance_animation] => Array
        (
            [sequence_entrance_animation] => 
            [sequence_entrance_animation_type] => none
            [sequence_entrance_animation_distance] => 
            [sequence_entrance_animation_duration] => 
            [sequence_entrance_animation_step] => 
            [sequence_entrance_animation_order] => 
            [sequence_entrance_animation_blur] => 
        )

    [ title_link_type] => Array
        (
            [title_link_type] => 
            [title_link_type_link_type] => post
            [title_link_type_meta_field] => 
        )

    [ dynamic_popup_select] => Array
        (
            [dynamic_popup_select] => 
            [dynamic_popup_select_link_type] => 
            [dynamic_popup_select_meta_field] => 
        )

    [ layout] => under
    [ custom_meta_text_before_five] => 
    [ custom_meta_icon_five] => fas fa-check
    [ custom_meta_icon_five_html] => <i class='fas fa-check'></i>
    [ meta_data_color] => #6AD5C3
    [ meta_data_typography] => Array
        (
            [typography] => custom
            [font_family] => Proxima Nova
            [font_size] => Array
                (
                    [unit] => px
                    [size] => 14
                    [sizes] => Array
                        (
                        )

                )

            [font_weight] => 400
            [text_transform] => uppercase
            [line_height] => Array
                (
                    [unit] => px
                    [size] => 22
                    [sizes] => Array
                        (
                        )

                )

            [letter_spacing] => Array
                (
                    [unit] => px
                    [size] => 1.38
                    [sizes] => Array
                        (
                        )

                )

            [font_style] => 
            [text_decoration] => 
            [word_spacing] => Array
                (
                    [unit] => px
                    [size] => 
                    [sizes] => Array
                        (
                        )

                )

        )

    [ meta_data_spacing] => 13px
    [ meta_data_spacing_unit] => px
    [ meta_data_spacing_nounit] => 13
    [ meta_data_spacing_tablet_unit] => px
    [ meta_data_spacing_tablet_nounit] => 
    [ meta_data_spacing_mobile_unit] => px
    [ meta_data_spacing_mobile_nounit] => 
    [ meta_data_gap] => 0px
    [ meta_data_gap_unit] => px
    [ meta_data_gap_nounit] => 0
    [ meta_data_gap_tablet_unit] => px
    [ meta_data_gap_tablet_nounit] => 
    [ meta_data_gap_mobile_unit] => px
    [ meta_data_gap_mobile_nounit] => 
    [ meta_data_icon_gap] => 0px
    [ meta_data_icon_gap_unit] => px
    [ meta_data_icon_gap_nounit] => 0
    [ meta_data_icon_gap_tablet_unit] => px
    [ meta_data_icon_gap_tablet_nounit] => 
    [ meta_data_icon_gap_mobile_unit] => px
    [ meta_data_icon_gap_mobile_nounit] => 
    [ show_custom_meta_five] => false
    [ meta_item_width] => auto
    [ meta_item_width_tablet] => 
    [ meta_item_width_mobile] => 
    [ meta_data_algin] => flex-start
    [ meta_data_algin_tablet] => 
    [ meta_data_algin_mobile] => 
    [ show_empty_message] => true
    [ no_posts_found] => No posts found
    [ message_typography] => Array
        (
            [typography] => 
            [font_family] => 
            [font_size] => 
            [font_weight] => 
            [text_transform] => 
            [font_style] => 
            [text_decoration] => 
            [line_height] => 
            [letter_spacing] => 
            [word_spacing] => 
        )

    [ message_color] => #000000
    [ message_background] => #e8e8e8
    [ messsage_radius] => Array
        (
            [unit] => px
            [top] => 
            [right] => 
            [bottom] => 
            [left] => 
            [isLinked] => 1
        )

    [ custom_meta_name_five] => 
    [ custom_meta_icon_four] => fas fa-check
    [ custom_meta_icon_four_html] => <i class='fas fa-check'></i>
    [ custom_meta_hr_copy_copy_copy] => 
    [ custom_meta_icon_two] => fas fa-check
    [ custom_meta_icon_two_html] => <i class='fas fa-check'></i>
    [ custom_meta_icon_hide] => false
    [ show_custom_meta_two] => false
    [ custom_meta_name_two] => 
    [ custom_meta_text_before_two] => 
    [ meta_field_two_convert] => no
    [ meta_two_date_source] => d/m/Y
    [ meta_two_date_dest] => d-m-y
    [ custom_meta_hr_copy] => 
    [ message_margin] => Array
        (
            [unit] => px
            [top] => 
            [right] => 
            [bottom] => 
            [left] => 
            [isLinked] => 1
        )

    [ show_custom_meta_three] => false
    [ custom_meta_name_three] => 
    [ custom_meta_text_before_three] => 
    [ custom_meta_icon_three] => fas fa-check
    [ custom_meta_icon_three_html] => <i class='fas fa-check'></i>
    [ custom_meta_hr_copy_copy] => 
    [ show_custom_meta_four] => false
    [ custom_meta_name_four] => 
    [ custom_meta_text_before_four] => 
    [ message_padding] => Array
        (
            [unit] => px
            [top] => 20
            [right] => 20
            [bottom] => 20
            [left] => 20
            [isLinked] => 1
        )

    [ image_fit] => Cover
    [ image_fit_tablet] => 
    [ image_fit_mobile] => 
    [ message_border] => Array
        (
            [border] => solid
            [width] => Array
                (
                    [unit] => px
                    [top] => 
                    [right] => 
                    [bottom] => 
                    [left] => 
                    [isLinked] => 1
                )

            [color] => #c4c4c4
        )

    [ icon_spacing] => 10
    [ icon_spacing_unit] => px
    [ icon_spacing_nounit] => 10
    [ icon_spacing_tablet_unit] => px
    [ icon_spacing_tablet_nounit] => 
    [ icon_spacing_mobile_unit] => px
    [ icon_spacing_mobile_nounit] => 
    [ show_button_icon] => false
    [ content_radius] => Array
        (
            [unit] => px
            [top] => 
            [right] => 
            [bottom] => 
            [left] => 
            [isLinked] => 1
        )

    [ content_shadow] => Array
        (
            [box_shadow_type] => 
            [box_shadow] => 
            [box_shadow_position] => 
        )

    [ content_border] => Array
        (
            [border] => 
            [width] => 
            [color] => 
            [hover_border] => 
            [hover_width] => 
            [hover_color] => 
            [active_border] => 
            [active_width] => 
            [active_color] => 
        )

    [ content_border_hover] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ content_border_active] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ button_icon] => fas fa-arrow-right
    [ button_icon_html] => <i class='fas fa-arrow-right'></i>
    [ show_post_counter_index] => false
    [ image_grow_on_hover] => false
    [ typography] => Array
        (
            [typography] => 
            [font_family] => 
            [font_size] => 
            [font_weight] => 
            [text_transform] => 
            [font_style] => 
            [text_decoration] => 
            [line_height] => 
            [letter_spacing] => 
            [word_spacing] => 
        )

    [ index_gap] => 10
    [ index_gap_unit] => px
    [ index_gap_nounit] => 10
    [ index_gap_tablet_unit] => px
    [ index_gap_tablet_nounit] => 
    [ index_gap_mobile_unit] => px
    [ index_gap_mobile_nounit] => 
    [ color] => 
    [ text_shadow] => Array
        (
            [box_shadow_type] => 
            [box_shadow] => 
            [box_shadow_position] => 
        )

    [ align_counter_index] => center
    [ align_counter_index_tablet] => 
    [ align_counter_index_mobile] => 
    [ image_scale_hover] => 
    [ image_scale_hover_unit] => %
    [ image_scale_hover_nounit] => 
    [ image_scale_hover_tablet_unit] => px
    [ image_scale_hover_tablet_nounit] => 
    [ image_scale_hover_mobile_unit] => px
    [ image_scale_hover_mobile_nounit] => 
    [ card_overflow] => hidden
    [ card_overflow_tablet] => 
    [ card_overflow_mobile] => 
    [ remote_parent] => Array
        (
            [attributes] => 
            [class] => 
            [click_event] => click
        )

    [ open_links_in_new_tab] => _self
    [ image_ratio] => 1 / 1
    [ image_ratio_tablet] => 
    [ image_ratio_mobile] => 
    [ image_scale] => 100%
    [ image_scale_unit] => %
    [ image_scale_nounit] => 100
    [ image_scale_tablet_unit] => px
    [ image_scale_tablet_nounit] => 
    [ image_scale_mobile_unit] => px
    [ image_scale_mobile_nounit] => 
    [ custom_meta_icon_one] => fas fa-check
    [ custom_meta_icon_one_html] => <i class='fas fa-check'></i>
    [ image_css_filter] => Array
        (
            [css_filter] => 
            [blur] => 
            [brightness] => 
            [contrast] => 
            [saturate] => 
            [hue] => 
            [hover_css_filter] => 
            [hover_blur] => 
            [hover_brightness] => 
            [hover_contrast] => 
            [hover_saturate] => 
            [hover_hue] => 
        )

    [ image_background_color] => #ffffff
    [ image_overlay_color] => 
    [ image_radius] => Array
        (
            [unit] => px
            [top] => 
            [right] => 
            [bottom] => 
            [left] => 
            [isLinked] => 1
        )

    [ image_border] => Array
        (
            [border] => 
            [width] => 
            [color] => 
            [copy_border] => 
            [copy_width] => 
            [copy_color] => 
        )

    [ image_shadow] => Array
        (
            [box_shadow_type] => 
            [box_shadow] => 
            [box_shadow_position] => 
            [hover_box_shadow_type] => 
            [hover_box_shadow] => 
            [hover_box_shadow_position] => 
        )

    [ image_css_filter_hover] => Array
        (
            [css_filter] => 
            [blur] => 
            [brightness] => 
            [contrast] => 
            [saturate] => 
            [hue] => 
        )

    [ avatar_radius] => 100px
    [ avatar_radius_unit] => px
    [ avatar_radius_nounit] => 100
    [ avatar_radius_tablet_unit] => px
    [ avatar_radius_tablet_nounit] => 
    [ avatar_radius_mobile_unit] => px
    [ avatar_radius_mobile_nounit] => 
    [ image_background_color_hover] => 
    [ image_overlay_color_hover] => 
    [ image_radius_hover] => Array
        (
            [unit] => px
            [top] => 
            [right] => 
            [bottom] => 
            [left] => 
            [isLinked] => 1
        )

    [ image_border_copy] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ image_shadow_hover] => Array
        (
            [box_shadow_type] => 
            [box_shadow] => 
            [box_shadow_position] => 
        )

    [ hover_animation] => 
    [ hr_author_avatar] => 
    [ avatar_size] => 30px
    [ avatar_size_unit] => px
    [ avatar_size_nounit] => 30
    [ avatar_size_tablet_unit] => px
    [ avatar_size_tablet_nounit] => 
    [ avatar_size_mobile_unit] => px
    [ avatar_size_mobile_nounit] => 
    [ custom_meta_hr] => 
    [ meta_one_date_source] => d/m/Y
    [ meta_one_date_dest] => d-m-y
    [ show_image] => true
    [ title_typography] => Array
        (
            [typography] => custom
            [font_family] => Proxima Nova
            [font_size] => Array
                (
                    [unit] => px
                    [size] => 20
                    [sizes] => Array
                        (
                        )

                )

            [font_weight] => 400
            [text_decoration] => underline
            [line_height] => Array
                (
                    [unit] => px
                    [size] => 35
                    [sizes] => Array
                        (
                        )

                )

            [letter_spacing] => Array
                (
                    [unit] => px
                    [size] => -0.2
                    [sizes] => Array
                        (
                        )

                )

            [text_transform] => 
            [font_style] => 
            [word_spacing] => Array
                (
                    [unit] => px
                    [size] => 
                    [sizes] => Array
                        (
                        )

                )

        )

    [ title_spacing] => 0px
    [ title_spacing_unit] => px
    [ title_spacing_nounit] => 0
    [ text_color] => #081D40
    [ text_typography] => Array
        (
            [typography] => custom
            [font_family] => Proxima Nova
            [font_size] => Array
                (
                    [unit] => px
                    [size] => 16
                    [sizes] => Array
                        (
                        )

                )

            [font_weight] => 400
            [line_height] => Array
                (
                    [unit] => px
                    [size] => 27
                    [sizes] => Array
                        (
                        )

                )

            [letter_spacing] => Array
                (
                    [unit] => px
                    [size] => -0.2
                    [sizes] => Array
                        (
                        )

                )

            [text_transform] => 
            [font_style] => 
            [text_decoration] => 
            [word_spacing] => Array
                (
                    [unit] => px
                    [size] => 
                    [sizes] => Array
                        (
                        )

                )

        )

    [ text_spacing] => 10px
    [ text_spacing_unit] => px
    [ text_spacing_nounit] => 10
    [ intro_number_of_characters] => 140
    [ item_radius] => 0px
    [ item_radius_unit] => px
    [ item_radius_nounit] => 0
    [ item_radius_tablet_unit] => px
    [ item_radius_tablet_nounit] => 
    [ item_radius_mobile_unit] => px
    [ item_radius_mobile_nounit] => 
    [ fallback_image] => https://www.evaluate.com/wp-content/uploads/ac_assets/uc_post_grid_style_one/no-image.png
    [ fallback_image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/ac_assets/uc_post_grid_style_one/no-image.png"
    [ fallback_image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/ac_assets/uc_post_grid_style_one/no-image.png"
    [ fallback_image_thumb] => https://www.evaluate.com/wp-content/uploads/ac_assets/uc_post_grid_style_one/no-image.png
    [ title_color] => #24576D
    [ show_category] => false
    [ disable_link_in_categories] => false
    [ cat_tax] => category
    [ add_coma_between_categories] => false
    [ cat_maxterms] => 10
    [ show_title] => true
    [ title_html_tag] => div
    [ title_color_hover] => 
    [ content_padding] => Array
        (
            [unit] => px
            [top] => 30
            [right] => 30
            [bottom] => 30
            [left] => 30
            [isLinked] => 1
        )

    [ show_text] => true
    [ button_bg_color] => #000000
    [ partial_overlay_spacing] => 20
    [ content_width] => 50
    [ content_width_unit] => px
    [ content_width_nounit] => 50
    [ content_width_tablet_unit] => px
    [ content_width_tablet_nounit] => 
    [ content_width_mobile_unit] => px
    [ content_width_mobile_nounit] => 
    [ grid_gap] => 150px
    [ grid_gap_unit] => px
    [ grid_gap_nounit] => 150
    [ grid_gap_tablet_unit] => px
    [ grid_gap_tablet_nounit] => 
    [ grid_gap_mobile_unit] => px
    [ grid_gap_mobile_nounit] => 
    [ number_of_items] => 3
    [ number_of_items_tablet] => 
    [ number_of_items_mobile] => 1
    [ button_text] => Read More
    [ button_padding] => Array
        (
            [unit] => px
            [top] => 10
            [right] => 20
            [bottom] => 10
            [left] => 20
            [isLinked] => 1
        )

    [ button_radius] => 0px
    [ button_radius_unit] => px
    [ button_radius_nounit] => 0
    [ button_background_color_hover] => 
    [ image_height] => 250px
    [ image_height_unit] => px
    [ image_height_nounit] => 250
    [ image_height_tablet_unit] => px
    [ image_height_tablet_nounit] => 
    [ image_height_mobile_unit] => px
    [ image_height_mobile_nounit] => 
    [ button_text_color] => #ffffff
    [ button_text_color_hover] => 
    [ button_spacing] => 10px
    [ button_spacing_unit] => px
    [ button_spacing_nounit] => 10
    [ button_spacing_tablet_unit] => px
    [ button_spacing_tablet_nounit] => 
    [ button_spacing_mobile_unit] => px
    [ button_spacing_mobile_nounit] => 
    [ button_border] => Array
        (
            [border] => 
            [width] => 
            [color] => 
            [hover_border] => 
            [hover_width] => 
            [hover_color] => 
        )

    [ button_border_hover] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ button_style] => inline-block
    [ alignment] => inherit
    [ alignment_tablet] => 
    [ alignment_mobile] => 
    [ height_type] => fixed
    [ disable_link_in_title] => false
    [ show_button] => false
    [ directional_hover] => false
    [ text_before_author] => 
    [ show_time] => false
    [ text_before_time] => 
    [ time_icon] => far fa-clock
    [ time_icon_html] => <i class='far fa-clock'></i>
    [ hr_copy2] => 
    [ show_author] => false
    [ author_element] => icon
    [ author_icon] => fas fa-user
    [ author_icon_html] => <i class='fas fa-user'></i>
    [ hr_copy] => 
    [ date_icon] => 
    [ date_icon_html] => <i class=''></i>
    [ show_comments] => false
    [ text_before_comments] => Comments:
    [ comments_icon] => fas fa-comment
    [ comments_icon_html] => <i class='fas fa-comment'></i>
    [ hr_copy_copy] => 
    [ show_custom_meta_one] => false
    [ custom_meta_name_one] => 
    [ custom_meta_text_before_one] => 
    [ meta_field_one_convert] => no
    [ hr_copy23] => 
    [ date_format] => 
    [ align_button_same_height] => false
    [ category_color] => #ffffff
    [ item_shadow] => Array
        (
            [box_shadow_type] => yes
            [box_shadow] => Array
                (
                    [horizontal] => 0
                    [vertical] => 0
                    [blur] => 10
                    [spread] => 0
                    [color] => rgba(0, 0, 0, 0.17)
                )

            [box_shadow_position] =>  
        )

    [ item_border] => Array
        (
            [border] => 
            [width] => 
            [color] => 
            [hover_border] => 
            [hover_width] => 
            [hover_color] => 
            [active_border] => 
            [active_width] => 
            [active_color] => 
        )

    [ item_border_hover] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ item_border_active] => Array
        (
            [border] => 
            [width] => 
            [color] => 
        )

    [ content_bg_type] => regular
    [ content_bg] => #FFFFFF
    [ content_bg_advanced] => Array
        (
            [content_bg_advanced] => 
            [content_bg_advanced_background] => 
            [content_bg_advanced_color] => 
            [content_bg_advanced_color_stop] => 
            [content_bg_advanced_color_b] => 
            [content_bg_advanced_color_b_stop] => 
            [content_bg_advanced_gradient_type] => 
            [content_bg_advanced_gradient_angle] => 
            [content_bg_advanced_gradient_position] => 
            [content_bg_advanced_image] => 
            [content_bg_advanced_position] => 
            [content_bg_advanced_xpos] => 
            [content_bg_advanced_ypos] => 
            [content_bg_advanced_attachment] => 
            [content_bg_advanced_repeat] => 
            [content_bg_advanced_size] => 
            [content_bg_advanced_bg_width] => 
            [content_bg_advanced_video_link] => 
            [content_bg_advanced_video_start] => 
            [content_bg_advanced_video_end] => 
            [content_bg_advanced_play_once] => 
            [content_bg_advanced_play_on_mobile] => 
            [content_bg_advanced_privacy_mode] => 
            [content_bg_advanced_video_fallback] => 
            [content_bg_advanced_slideshow_gallery] => 
            [content_bg_advanced_slideshow_loop] => 
            [content_bg_advanced_slideshow_slide_duration] => 
            [content_bg_advanced_slideshow_slide_transition] => 
            [content_bg_advanced_slideshow_transition_duration] => 
            [content_bg_advanced_slideshow_background_size] => 
            [content_bg_advanced_slideshow_background_position] => 
            [content_bg_advanced_slideshow_lazyload] => 
            [content_bg_advanced_slideshow_ken_burns] => 
            [content_bg_advanced_slideshow_ken_burns_zoom_direction] => 
        )

    [ category_background] => #545454
    [ text_before_date] => 
    [ category_typography] => Array
        (
            [typography] => 
            [font_family] => 
            [font_size] => 
            [font_weight] => 
            [text_transform] => 
            [font_style] => 
            [text_decoration] => 
            [line_height] => 
            [letter_spacing] => 
            [word_spacing] => 
        )

    [ category_spacing] => 0px
    [ category_spacing_unit] => px
    [ category_spacing_nounit] => 0
    [ category_spacing_tablet_unit] => px
    [ category_spacing_tablet_nounit] => 
    [ category_spacing_mobile_unit] => px
    [ category_spacing_mobile_nounit] => 
    [ category_padding] => Array
        (
            [unit] => px
            [top] => 3
            [right] => 5
            [bottom] => 3
            [left] => 5
            [isLinked] => 1
        )

    [ category_radius] => Array
        (
            [unit] => px
            [top] => 3
            [right] => 3
            [bottom] => 3
            [left] => 3
            [isLinked] => 1
        )

    [ button_typography] => Array
        (
            [typography] => 
            [font_family] => 
            [font_size] => 
            [font_weight] => 
            [text_transform] => 
            [font_style] => 
            [text_decoration] => 
            [line_height] => 
            [letter_spacing] => 
            [word_spacing] => 
        )

    [ debug_meta_fields] => false
    [ hr] => 
    [ show_date] => true
    [ post_list] => 
    [ uc_filtering_attributes] =>  data-ajax='true'  data-filterbehave='ajax'  querydata='{&quot;count_posts&quot;:6,&quot;total_posts&quot;:155,&quot;page&quot;:1,&quot;num_pages&quot;:26,&quot;orderdir&quot;:&quot;desc&quot;}'
    [ uc_filtering_addclass] =>  uc-filterable-grid
    [ post_list_output_ids] => 7570,7436,7385,7052,7048,6677
    [ post_list_imagesize] => medium
    [ post_list_include_date_meta_format] => 
    [ post_list_category] => Array
        (
        )

    [ post_list_maxitems] => 6
    [ post_list_isajax] => true
    [ post_list_orderdir1] => DESC
    [ post_list_posttype] => Array
        (
            [0] => post
            [1] => thought-leadership
            [2] => press_release
            [3] => webinar
        )

    [ post_list_excludeby] => Array
        (
            [0] => specific_posts
        )

    [ post_list_exclude_specific_posts] => Array
        (
            [0] => 7515
            [1] => 7513
        )

    [ post_list_show_query_debug] => 
    [ post_list_source] => custom
    [ post_list_related_mode] => 
    [ post_list_includeby] => Array
        (
        )

    [ post_list_includeby_authors] => 
    [ post_list_includeby_authors_dynamic] => 
    [ post_list_includeby_date] => 
    [ post_list_include_date_after] => 
    [ post_list_include_date_before] => 
    [ post_list_include_date_meta] => 
    [ post_list_includeby_parent] => 
    [ post_list_includeby_parent_addparent] => 
    [ post_list_includeby_metakey] => 
    [ post_list_includeby_metacompare] => 
    [ post_list_includeby_metavalue] => 
    [ post_list_includeby_metavalue2] => 
    [ post_list_includeby_metavalue3] => 
    [ post_list_includeby_meta_addsecond] => 
    [ post_list_includeby_second_metakey] => 
    [ post_list_includeby_second_metacompare] => 
    [ post_list_includeby_second_metavalue] => 
    [ post_list_includeby_meta_relation] => 
    [ post_list_includeby_meta_debug] => 
    [ post_list_includeby_function_name] => 
    [ post_list_includeby_function_addparam] => 
    [ post_list_includeby_postmeta_postid] => 
    [ post_list_includeby_postmeta_metafield] => 
    [ post_list_includeby_dynamic_field] => 
    [ post_list_includeby_terms_dynamic_field] => 
    [ post_list_includeby_terms_from_meta] => 
    [ post_list_category_relation] => AND
    [ post_list_terms_include_children] => 
    [ post_list_manual_select_post_ids] => 
    [ post_list_manual_post_ids_dynamic] => 
    [ post_list_manual_avoid_duplicates] => 
    [ post_list_related_taxonomies] => 
    [ post_list_exclude_dynamic_field] => 
    [ post_list_exclude_terms] => 
    [ post_list_excludeby_authors] => 
    [ post_list_offset] => 
    [ post_list_terms_exclude_children] => 
    [ post_list_status] => Array
        (
            [0] => publish
        )

    [ post_list_posttype_current] => 
    [ post_list_maxitems_current] => 
    [ post_list_orderby] => default
    [ post_list_orderby_meta_key1] => 
    [ post_list_queryid] => 
    [ post_list_query_debug_type] => 
    [ post_list_ajax_seturl] => ajax
    [ post_list_filtering_group] => 
    [ post_list_disable_other_hooks] => 
    [ post_list_pagination_type] => 
)
Widget Items Data
Array
(
    [0] => Array
        (
            [ id] => 7570
            [ title] => Meet the Evaluate Team: Markella Kordoyanni
            [ alias] => meet-the-evaluate-team-markella-kordoyanni
            [ author_id] => 30
            [ post_type] => post
            [ content] => <h2><strong>Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay on top of the latest developments and are able to deliver timely insights to their stakeholders. I caught up with Markella to learn about what makes her tick, including being involved in clinical trials for world-class drugs and how the pharmaceutical industry’s gain was music’s loss. </strong></h2>
<p><img class="wp-image-7575 size-medium alignright" src="https://www.evaluate.com/wp-content/uploads/2024/03/evaluate-author-markella-300x300.png" alt="evaluate-author-markella-headshot" width="300" height="300" srcset="https://www.evaluate.com/wp-content/uploads/2024/03/evaluate-author-markella-300x300.png 300w, https://www.evaluate.com/wp-content/uploads/2024/03/evaluate-author-markella-150x150.png 150w, https://www.evaluate.com/wp-content/uploads/2024/03/evaluate-author-markella.png 500w" sizes="(max-width: 300px) 100vw, 300px" /></p>
<ol>
<li><strong>What do you think is going to have the biggest impact on the pharma industry in the next five years?</strong><br />
Generative AI is increasingly a part of many aspects of healthcare and the pharma industry. Despite geopolitical, economic and ethical headwinds, the trajectory of AI is upwards. And while the focus of <a href="https://www.evaluate.com/thought-leadership/ai-powered-portfolio-decisions/">AI in biopharma</a> has so far been on the drug discovery/research, pre-clinical and clinical development side, I think there will be more activity on the regulatory and commercial part of the value chain. I believe we are in the midst of a turning point in history and I am both optimistic and excited to see all the potential applications of this tool in our industry.</li>
<li><strong>What’s the biggest challenge facing pharma and biotech companies at the moment</strong><br />
It’s hard to point to one challenge as being the biggest, but one that’s top of mind for many of our clients, particularly in <a href="https://www.evaluate.com/solutions/competitive-intelligence/">competitive intelligence</a> is making sense of data – which is often where our team comes in. Specifically, helping companies understand what data is most important for them, interpret ever-increasing data into insights and translate that into implications for their company. Companies that know how to get to <a href="https://www.evaluate.com/blog/competitive-intelligence-and-the-quest-for-the-single-source-of-truth/">actionable intelligence</a> are in a better position to anticipate and prepare for hurdles ahead and fail early, fail faster or pivot.</li>
<li><strong>Which areas of the industry are you most fascinated by? Why?</strong><br />
Oncology remains a very important therapy area for me and although we have seen incredible progress over the years in some indications such as breast, melanoma, non-small cell lung cancer, there is still so much more that needs to be done in other indications where survival rates are low and patients have very little options (i.e. pancreatic cancer, glioblastoma, ovarian etc.). I am optimistic that with certain new technologies such as bispecific antibodies coming of age, there will be progress in those areas. And while a lot of my work has been focused on oncology over the years, I am very excited about the CNS space especially as a result of some of the recent projects I’ve been involved with.</li>
<li><strong> Other than working for Evaluate (of course!), what’s your career highlight to-date?</strong><br />
Being involved in several Phase II and III drugs that made it to the market and improved patient care. I am proud to say I have a few of those under my belt such as Kadcyla, Dupixent (dupilumab), Quinlock (ripretinib), Collategene, among others.<br />
Most recently, I have been involved in government projects and it has been an extremely rewarding and eye-opening experience to see how some of those programmes run. We are currently supporting the US Department of Defense (DOD) and industry partners with a <a href="https://clinicaltrials.gov/study/NCT05422612">unique Phase II trial</a> that will help veterans suffering from PTSD. Our work, a true collaborative project and partnership with the U.S. Army Medical Research and Development Command has already resulted in four potential treatments tested in this trial and there are plans to identify more in the future depending on the trial’s progress. I am proud to say that our work is enabling patients get access to drugs in a segment that is not being served by conventional R&amp;D.</li>
<li><strong>What’s the best thing about your role?</strong><br />
The first thing is that I am surrounded by intelligent, driven and inspiring colleagues and I manage extremely talented, humble and good human beings! The second is the variety of work in the projects I get to pitch, close and deliver. No one project is exactly the same and clients always keep me on my toes. There is never a dull moment in consulting!</li>
<li><strong>What’s your favourite drink?</strong><br />
Red wine. I confess I am no wine buff or connoisseur, but it means I am easily pleased. I love all types of red wine!</li>
<li><strong>Tell us an interesting fact about yourself</strong><br />
I could read music before I could read the alphabet. I started playing the piano when I was five and wanted to be a piano teacher up until I was introduced to biology, at which point I became completely fascinated and curious about the cell and decided to go into the life sciences.</li>
</ol>

            [ link] => https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/
            [ link_attributes] => aria-label="Read more about Meet the Evaluate Team: Markella Kordoyanni" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/'
            [ excerpt] => 
            [ intro] => Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on...
            [ intro_full] => Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay on top of the latest developments and are able to deliver timely insights to their stakeholders. I caught up with Markella to learn about what makes her tick, including being involved in clinical trials for world-class drugs and how the pharmaceutical industry’s gain was music’s loss. 


What do you think is going to have the biggest impact on the pharma industry in the next five years?
Generative AI is increasingly a part of many aspects of healthcare and the pharma industry. Despite geopolitical, economic and ethical headwinds, the trajectory of AI is upwards. And while the focus of AI in biopharma has so far been on the drug discovery/research, pre-clinical and clinical development side, I think there will be more activity on the regulatory and commercial part of the value chain. I believe we are in the midst of a turning point in history and I am both optimistic and excited to see all the potential applications of this tool in our industry.
What’s the biggest challenge facing pharma and biotech companies at the moment
It’s hard to point to one challenge as being the biggest, but one that’s top of mind for many of our clients, particularly in competitive intelligence is making sense of data – which is often where our team comes in. Specifically, helping companies understand what data is most important for them, interpret ever-increasing data into insights and translate that into implications for their company. Companies that know how to get to actionable intelligence are in a better position to anticipate and prepare for hurdles ahead and fail early, fail faster or pivot.
Which areas of the industry are you most fascinated by? Why?
Oncology remains a very important therapy area for me and although we have seen incredible progress over the years in some indications such as breast, melanoma, non-small cell lung cancer, there is still so much more that needs to be done in other indications where survival rates are low and patients have very little options (i.e. pancreatic cancer, glioblastoma, ovarian etc.). I am optimistic that with certain new technologies such as bispecific antibodies coming of age, there will be progress in those areas. And while a lot of my work has been focused on oncology over the years, I am very excited about the CNS space especially as a result of some of the recent projects I’ve been involved with.
 Other than working for Evaluate (of course!), what’s your career highlight to-date?
Being involved in several Phase II and III drugs that made it to the market and improved patient care. I am proud to say I have a few of those under my belt such as Kadcyla, Dupixent (dupilumab), Quinlock (ripretinib), Collategene, among others.
Most recently, I have been involved in government projects and it has been an extremely rewarding and eye-opening experience to see how some of those programmes run. We are currently supporting the US Department of Defense (DOD) and industry partners with a unique Phase II trial that will help veterans suffering from PTSD. Our work, a true collaborative project and partnership with the U.S. Army Medical Research and Development Command has already resulted in four potential treatments tested in this trial and there are plans to identify more in the future depending on the trial’s progress. I am proud to say that our work is enabling patients get access to drugs in a segment that is not being served by conventional R&amp;D.
What’s the best thing about your role?
The first thing is that I am surrounded by intelligent, driven and inspiring colleagues and I manage extremely talented, humble and good human beings! The second is the variety of work in the projects I get to pitch, close and deliver. No one project is exactly the same and clients always keep me on my toes. There is never a dull moment in consulting!
What’s your favourite drink?
Red wine. I confess I am no wine buff or connoisseur, but it means I am easily pleased. I love all types of red wine!
Tell us an interesting fact about yourself
I could read music before I could read the alphabet. I started playing the piano when I was five and wanted to be a piano teacher up until I was introduced to biology, at which point I became completely fascinated and curious about the cell and decided to go into the life sciences.
            [ date] => 1711649431
            [ date_modified] => 1711651466
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-300x157.jpg
            [ image_width] => 300
            [ image_height] => 157
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-1024x536.jpg
            [ image_thumb_large_width] => 1024
            [ image_thumb_large_height] => 536
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-768x402.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 402
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-300x157.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 157
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495.jpg
            [ image_thumb_1536x1536_width] => 1200
            [ image_thumb_1536x1536_height] => 628
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495.jpg
            [ image_thumb_2048x2048_width] => 1200
            [ image_thumb_2048x2048_height] => 628
            [ image_title] => wordpress-featured-image_adobestock_93974495
            [ image_alt] => team meeting photo
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 7577
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-300x157.jpg" alt="team meeting photo"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/wordpress-featured-image_adobestock_93974495-300x157.jpg" alt="team meeting photo" width="300" height="157"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_author_image_ID] => 5886
            [ cf_author_image_id] => 5886
            [ cf_author_image_title] => Evaluate-Author-Carolyn Hall
            [ cf_author_image_filename] => Evaluate-Author-Carolyn-Hall.png
            [ cf_author_image_filesize] => 307786
            [ cf_author_image_url] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall.png
            [ cf_author_image_link] => https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-2024-preview-webinar/attachment/evaluate-author-carolyn-hall/
            [ cf_author_image_alt] => Evaluate-Author-Carolyn-Hall
            [ cf_author_image_author] => 12
            [ cf_author_image_description] => 
            [ cf_author_image_caption] => 
            [ cf_author_image_name] => evaluate-author-carolyn-hall
            [ cf_author_image_status] => inherit
            [ cf_author_image_uploaded_to] => 5792
            [ cf_author_image_date] => 2024-02-13 19:02:28
            [ cf_author_image_modified] => 2024-02-13 19:02:38
            [ cf_author_image_menu_order] => 0
            [ cf_author_image_mime_type] => image/png
            [ cf_author_image_type] => image
            [ cf_author_image_subtype] => png
            [ cf_author_image_icon] => https://www.evaluate.com/wp-includes/images/media/default.png
            [ cf_author_image_width] => 500
            [ cf_author_image_height] => 500
            [ cf_author_image_sizes] => Array
                (
                    [thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall-150x150.png
                    [thumbnail-width] => 150
                    [thumbnail-height] => 150
                    [medium] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall-300x300.png
                    [medium-width] => 300
                    [medium-height] => 300
                    [medium_large] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall.png
                    [medium_large-width] => 500
                    [medium_large-height] => 500
                    [large] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall.png
                    [large-width] => 500
                    [large-height] => 500
                    [1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall.png
                    [1536x1536-width] => 500
                    [1536x1536-height] => 500
                    [2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/02/Evaluate-Author-Carolyn-Hall.png
                    [2048x2048-width] => 500
                    [2048x2048-height] => 500
                )

            [ cf_author] => Carolyn Hall
            [ cf_author_title] => Director, Content & Thought Leadership Marketing
            [ cf_form_field] => 
            [ cf_author_image_copy] => 
            [ cf_author_copy] => 
            [ cf_author_title_copy] => 
            [ category_id] => 33
            [ category_name] => Blog
            [ category_slug] => blog
            [ category_link] => https://www.evaluate.com/category/blog/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 33
                            [slug] => blog
                            [name] => Blog
                            [description] => 
                            [link] => https://www.evaluate.com/category/blog/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 56
                        )

                )

        )

    [1] => Array
        (
            [ id] => 7436
            [ title] => Competitive Intelligence Insights: Cell & Gene Therapy
            [ alias] => competitive-intelligence-insights-cell-gene-therapy
            [ author_id] => 30
            [ post_type] => post
            [ content] => <p>The number of cell and gene therapy (C&amp;GT)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is plenty to consider.</p>
<p>Although early innovations in C&amp;GT have been spearheaded by small biotechs, Big Pharma quickly followed suit with major deals to jumpstart their own in-house programmes. Whilst this means that deal volume in the space may slow in the medium-to-long term, their value may continue to increase as Big Pharma’s search for high value disease portfolio lynchpins also continues. Big Pharma’s competitive edge over biotech market entrants will be most evident in how it deploys its in-house capacity and capabilities to accelerate time to market or acquire complementary therapies to strategically bolster its portfolios.</p>
<h2><strong>What does this mean for biotechs – and what do CI teams need to focus on?</strong></h2>
<p>New biotech entrants to the C&amp;GT space need to remain vigilant of Big Pharma and other biotech competitors alike, but for different reasons.</p>
<ul>
<li><strong>Biotech companies:</strong> These pose an inherent threat as they seek to manage their relatively smaller budgets to maximum value. Biotech C&amp;GT companies may benefit from tracking competitors’ earnings calls and general corporate communications, senior/executive hires and overall headcount, and funding plus general deal-making activities.</li>
<li><strong>Big Pharma:</strong> Monitoring Big Pharma deal trends and their appetite for specific C&amp;GT modalities will also provide valuable directional intelligence on which fellow biotechs might be next up for a landscape-shifting deal.</li>
</ul>
<h2><strong>Where do the Big Pharma players need to focus?</strong></h2>
<p>Big pharma players in C&amp;GT face identical <a href="https://www.evaluate.com/solutions/competitive-intelligence/">competitive intelligence</a> challenges, but often with the additional need to monitor competitors’ portfolios where there is significant overlap in pipeline and portfolio strategies. In addition to <a href="https://www.evaluate.com/use-case/competitive-landscape-analysis/">competitive intelligence</a> tracking, Big Pharma players may also benefit from monitoring for business development purposes, ensuring regular updates on key landscape events and catalysts to inform potential M&amp;A activities.</p>
<p>On the M&amp;A front, appetite for partnerships around cell and gene therapies has varied over the past few years. Gene therapies had attracted around $14.5bn deal dollars and 23 deals in 2021 across a variety of therapy areas, according to <a href="https://www.evaluate.com/solutions/evaluate-pharma/">Evaluate Pharma</a>. However, deal volume dropped to just eight in 2022, with total deal value reduced to $4.7bn, although sizeable deals were still made with Novartis partnering with Voyager Therapeutics for $1.8bn.</p>
<p>As the cell and gene therapy space continues to grow and expand, so will the need for a well-organised and well-resourced CI function to ensure successful and sustainable growth for big pharma and small biotech players alike. Our upcoming report, designed to give <a href="https://www.evaluate.com/solutions/competitive-intelligence/">CI teams</a> a clear view in to the C&amp;G landscape will dig into much more detail, including the indications getting the most attention, the top players and the trends in dealmaking. We’ll publish the report soon, so keep an eye out!</p>

            [ link] => https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/
            [ link_attributes] => aria-label="Read more about Competitive Intelligence Insights: Cell &amp; Gene Therapy" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/'
            [ excerpt] => 
            [ intro] => The number of cell and gene therapy (C&amp;GT)-based treatments in development has increased significantly...
            [ intro_full] => The number of cell and gene therapy (C&amp;GT)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is plenty to consider.
Although early innovations in C&amp;GT have been spearheaded by small biotechs, Big Pharma quickly followed suit with major deals to jumpstart their own in-house programmes. Whilst this means that deal volume in the space may slow in the medium-to-long term, their value may continue to increase as Big Pharma’s search for high value disease portfolio lynchpins also continues. Big Pharma’s competitive edge over biotech market entrants will be most evident in how it deploys its in-house capacity and capabilities to accelerate time to market or acquire complementary therapies to strategically bolster its portfolios.
What does this mean for biotechs – and what do CI teams need to focus on?
New biotech entrants to the C&amp;GT space need to remain vigilant of Big Pharma and other biotech competitors alike, but for different reasons.

Biotech companies: These pose an inherent threat as they seek to manage their relatively smaller budgets to maximum value. Biotech C&amp;GT companies may benefit from tracking competitors’ earnings calls and general corporate communications, senior/executive hires and overall headcount, and funding plus general deal-making activities.
Big Pharma: Monitoring Big Pharma deal trends and their appetite for specific C&amp;GT modalities will also provide valuable directional intelligence on which fellow biotechs might be next up for a landscape-shifting deal.

Where do the Big Pharma players need to focus?
Big pharma players in C&amp;GT face identical competitive intelligence challenges, but often with the additional need to monitor competitors’ portfolios where there is significant overlap in pipeline and portfolio strategies. In addition to competitive intelligence tracking, Big Pharma players may also benefit from monitoring for business development purposes, ensuring regular updates on key landscape events and catalysts to inform potential M&amp;A activities.
On the M&amp;A front, appetite for partnerships around cell and gene therapies has varied over the past few years. Gene therapies had attracted around $14.5bn deal dollars and 23 deals in 2021 across a variety of therapy areas, according to Evaluate Pharma. However, deal volume dropped to just eight in 2022, with total deal value reduced to $4.7bn, although sizeable deals were still made with Novartis partnering with Voyager Therapeutics for $1.8bn.
As the cell and gene therapy space continues to grow and expand, so will the need for a well-organised and well-resourced CI function to ensure successful and sustainable growth for big pharma and small biotech players alike. Our upcoming report, designed to give CI teams a clear view in to the C&amp;G landscape will dig into much more detail, including the indications getting the most attention, the top players and the trends in dealmaking. We’ll publish the report soon, so keep an eye out!
            [ date] => 1711536578
            [ date_modified] => 1711563179
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-300x200.jpg
            [ image_width] => 300
            [ image_height] => 200
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-1024x683.jpg
            [ image_thumb_large_width] => 1024
            [ image_thumb_large_height] => 683
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-768x512.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 512
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-300x200.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 200
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene.jpg
            [ image_thumb_1536x1536_width] => 1200
            [ image_thumb_1536x1536_height] => 800
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene.jpg
            [ image_thumb_2048x2048_width] => 1200
            [ image_thumb_2048x2048_height] => 800
            [ image_title] => cell gene
            [ image_alt] => cell-gene-abstract-image
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 7439
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-300x200.jpg" alt="cell-gene-abstract-image"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/cell-gene-300x200.jpg" alt="cell-gene-abstract-image" width="300" height="200"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_author_image_ID] => 5894
            [ cf_author_image_id] => 5894
            [ cf_author_image_title] => Evaluate-Author-Alex Bour
            [ cf_author_image_filename] => Evaluate-Author-Alex-Bour.png
            [ cf_author_image_filesize] => 251311
            [ cf_author_image_url] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour.png
            [ cf_author_image_link] => https://www.evaluate.com/blog/competitive-intelligence-and-the-quest-for-the-single-source-of-truth/attachment/evaluate-author-alex-bour/
            [ cf_author_image_alt] => Evaluate-Author-Alex-Bour
            [ cf_author_image_author] => 12
            [ cf_author_image_description] => 
            [ cf_author_image_caption] => 
            [ cf_author_image_name] => evaluate-author-alex-bour
            [ cf_author_image_status] => inherit
            [ cf_author_image_uploaded_to] => 5762
            [ cf_author_image_date] => 2024-02-13 19:39:39
            [ cf_author_image_modified] => 2024-02-13 19:39:55
            [ cf_author_image_menu_order] => 0
            [ cf_author_image_mime_type] => image/png
            [ cf_author_image_type] => image
            [ cf_author_image_subtype] => png
            [ cf_author_image_icon] => https://www.evaluate.com/wp-includes/images/media/default.png
            [ cf_author_image_width] => 500
            [ cf_author_image_height] => 500
            [ cf_author_image_sizes] => Array
                (
                    [thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour-150x150.png
                    [thumbnail-width] => 150
                    [thumbnail-height] => 150
                    [medium] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour-300x300.png
                    [medium-width] => 300
                    [medium-height] => 300
                    [medium_large] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour.png
                    [medium_large-width] => 500
                    [medium_large-height] => 500
                    [large] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour.png
                    [large-width] => 500
                    [large-height] => 500
                    [1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour.png
                    [1536x1536-width] => 500
                    [1536x1536-height] => 500
                    [2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Alex-Bour.png
                    [2048x2048-width] => 500
                    [2048x2048-height] => 500
                )

            [ cf_author] => Alex Bour, Ph.D
            [ cf_author_title] => Principle, Competitive Intelligence Practice Lead, Norstella
            [ cf_author_image_copy] => 
            [ cf_author_copy] => 
            [ cf_author_title_copy] => 
            [ cf_form_field] => 
            [ category_id] => 33
            [ category_name] => Blog
            [ category_slug] => blog
            [ category_link] => https://www.evaluate.com/category/blog/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 33
                            [slug] => blog
                            [name] => Blog
                            [description] => 
                            [link] => https://www.evaluate.com/category/blog/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 56
                        )

                )

        )

    [2] => Array
        (
            [ id] => 7385
            [ title] => EVALUATING: Neurology
            [ alias] => evaluating-neurology
            [ author_id] => 30
            [ post_type] => thought-leadership
            [ content] => <p>Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity&#8217;s, emerges from years of underinvestment, resulting in a landscape filled with unmet needs and appealing commercial prospects amid scant competition.</p>
<p>There’s plenty to go after: the neurology arena encompasses widespread degenerative conditions like Alzheimer’s or Parkinson’s, as well as epilepsy, depression, migraine, pain and multiple rare diseases.</p>
<p>In this eBook, Evaluate provides a snapshot of some of the most interesting players in the field, looking at their pipeline highlights, marketed drugs and what makes them ones to watch.</p>
<p>HIGHLIGHTS</p>
<ul>
<li>The Alzheimer’s landscape opens up</li>
<li>Past failures are resurrected</li>
<li>Street drugs are medicalised</li>
<li>Promising molecules and mechanisms emerge</li>
</ul>
<p><a class="turtl-embed" style="width: 340px; max-width: 100%;" title="EVALUATING: Neurology" href="https://evaluate.turtl.co/story/evaluating-neurology/?teaser=yes" target="_blank" rel="noopener" data-turtl-embed-type="animation" data-turtl-link-text="Click to read" data-turtl-width="340" data-turtl-display-mode="lightbox" data-turtl-animation-mode="hover" data-turtl-color="#1eb1c7" data-turtl-story-id="65f05363a642fc9e07766ba8">Click to read EVALUATING: Neurology</a><br />
<!-- Please call embed.js only once per page --><br />
<script async type="text/javascript" data-turtl-script="embed" data-turtl-assets-hostname=" https://assets.turtl.co" src=" https://app-static.turtl.co/embed/turtl.embed.v1.js"></script></p>

            [ link] => https://www.evaluate.com/thought-leadership/evaluating-neurology/
            [ link_attributes] => aria-label="Read more about EVALUATING: Neurology" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/thought-leadership/evaluating-neurology/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/thought-leadership/evaluating-neurology/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/thought-leadership/evaluating-neurology/'
            [ excerpt] => 
            [ intro] => Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements...
            [ intro_full] => Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity&#8217;s, emerges from years of underinvestment, resulting in a landscape filled with unmet needs and appealing commercial prospects amid scant competition.
There’s plenty to go after: the neurology arena encompasses widespread degenerative conditions like Alzheimer’s or Parkinson’s, as well as epilepsy, depression, migraine, pain and multiple rare diseases.
In this eBook, Evaluate provides a snapshot of some of the most interesting players in the field, looking at their pipeline highlights, marketed drugs and what makes them ones to watch.
HIGHLIGHTS

The Alzheimer’s landscape opens up
Past failures are resurrected
Street drugs are medicalised
Promising molecules and mechanisms emerge

Click to read EVALUATING: Neurology
            [ date] => 1710947300
            [ date_modified] => 1711621303
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-300x157.jpg
            [ image_width] => 300
            [ image_height] => 157
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-1024x536.jpg
            [ image_thumb_large_width] => 1024
            [ image_thumb_large_height] => 536
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-768x402.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 402
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-300x157.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 157
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201.jpg
            [ image_thumb_1536x1536_width] => 1200
            [ image_thumb_1536x1536_height] => 628
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201.jpg
            [ image_thumb_2048x2048_width] => 1200
            [ image_thumb_2048x2048_height] => 628
            [ image_title] => WordPress Featured Image_AdobeStock_638291201
            [ image_alt] => Biopharma-2022-Whats-Next-featured-image
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 6411
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-300x157.jpg" alt="Biopharma-2022-Whats-Next-featured-image"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2023/11/WordPress-Featured-Image_AdobeStock_638291201-300x157.jpg" alt="Biopharma-2022-Whats-Next-featured-image" width="300" height="157"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_intro_text] => 
            [ cf_button_cta] => 
            [ cf_button_text] => LEARN MORE
            [ cf_form_field] => 
            [ category_id] => 42
            [ category_name] => Report/eBook
            [ category_slug] => report-ebook
            [ category_link] => https://www.evaluate.com/category/report-ebook/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 42
                            [slug] => report-ebook
                            [name] => Report/eBook
                            [description] => 
                            [link] => https://www.evaluate.com/category/report-ebook/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 46
                        )

                )

        )

    [3] => Array
        (
            [ id] => 7052
            [ title] => Inpart and Evaluate Announce Strategic Partnership to Optimise Biopharma Dealmaking
            [ alias] => inpart-and-evaluate-announce-strategic-partnership-to-optimise-biopharma-dealmaking
            [ author_id] => 10
            [ post_type] => press_release
            [ content] => <p><strong>Lyon, France 4th March 2024:</strong> In a landmark collaboration, Inpart (previously Inova), a trailblazing software provider specialising in biopharma partnering, and Evaluate, a leading insights provider for the biopharma industry and part of Norstella, have officially announced their strategic partnership. This alliance will empower biopharma partnering teams to assess their opportunities quickly and efficiently with decisive data, in the same place.</p>
<p>Inpart&#8217;s flagship product, Deal, enables pharmaceutical companies and biotechs to identify, evaluate, and collaborate seamlessly on strategic partnerships. Paired with Evaluate’s unparalleled AI-enabled intelligence and forecasting solutions, this partnership promises to enhance the impact of critical data by providing direct accessibility for dealmakers when identifying and evaluating opportunities.</p>
<p><strong>Gilles Toulemonde, CEO of Inpart,</strong> &#8220;Incorporating Evaluate into our partnering CRM is integrating data into organisation. This is increasing productivity by increasing data quality and integrity. All connected sources are automatically synced and updated to save time and support informed decision-making. Essentially, we&#8217;re empowering our clients to establish trust in their data for the purpose of achieving operational excellence.&#8221;</p>
<p><strong>Chris Kelley, Chief Revenue Officer, Evaluate</strong> “This collaboration is strategically designed to foster robust dissemination and collaboration within dealmaking teams by directly embedding Evaluate data in their Inpart workflow – enabling more informed decision-making to help smooth the path of lifesaving therapies from pipeline to patient.”</p>
<p>This strategic partnership underscores the commitment of both companies to advancing the biopharma industry by facilitating stronger collaboration and empowering decision-makers with the tools they need to drive success.</p>
<p><strong>About Inpart:</strong><br />
Inpart is the trusted partner for biopharma and science partnering. The platform provide comprehensive solutions to facilitate, optimize and track interactions in the biopharma, scientific and academic sectors. Inpart’s technology is the preferred choice for more than 6,500 companies including 45/50 of the world&#8217;s leading pharma companies, 25/25 global R&amp;D intensive firms, 25/25 top EU R&amp;D intensive firms and over 200 of the world’s leading universities. <a href="https://www.inpart.io/products/connect" target="_blank" rel="noopener">Connect,</a> a cutting-edge match making platform, serves as the backbone of a thriving network, uniting over 6,500 industry professionals, academic organizations, biotech companies and investors. Through Connect, Inpart empower users to enhance their visibility, expedite partner discovery, and gain invaluable strategic insights.</p>
<p>Inpart&#8217;s partnering CRM, <a href="https://www.inpart.io/products/deal" target="_blank" rel="noopener">Deal,</a> is tailored specifically to meet the unique demands of the biopharma sector. Deal streamlines the collaboration and alliance management phases of biopharma partnerships, ensuring efficient and organized operations in executing Biopharma deals.</p>
<p>Discover the suite of products and services: <a href="http://www.inpart.io/" target="_blank" rel="noopener">www.inpart.io</a> and follow us on <a href="https://www.linkedin.com/company/inpart-io" target="_blank" rel="noopener">LinkedIn</a>.</p>
<p><strong>About Evaluate</strong><br />
Since 1996, Evaluate, a Norstella company, has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary and industry data into their workflows, tools and processes so they can work more effectively and efficiently.<br />
For more information about Evaluate, <a href="https://www.evaluate.com">visit www.evaluate.com</a> and follow us on <a href="https://www.linkedin.com/company/evaluatepharma" target="_blank" rel="noopener">LinkedIn</a> and <a href="https://twitter.com/evaluatepharma" target="_blank" rel="noopener">Twitter</a>.</p>
<p><strong>About Norstella</strong><br />
Norstella consists of several prominent pharmaceutical solutions providers—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group—united by a shared mission: to smooth the path to life-saving therapies for patients and providers. Norstella offers comprehensive insights throughout the drug development lifecycle, leveraging unparalleled data, cutting-edge technology, and expert insights and consultancy. For more information, <a href="https://www.norstella.com/" target="_blank" rel="noopener">visit Norstella</a> and follow on <a href="https://www.linkedin.com/company/norstellacompany" target="_blank" rel="noopener">LinkedIn</a>.</p>

            [ link] => https://www.evaluate.com/press_release/inpart-and-evaluate-announce-strategic-partnership-to-optimise-biopharma-dealmaking/
            [ link_attributes] => aria-label="Read more about Inpart and Evaluate Announce Strategic Partnership to Optimise Biopharma Dealmaking" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/press_release/inpart-and-evaluate-announce-strategic-partnership-to-optimise-biopharma-dealmaking/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/press_release/inpart-and-evaluate-announce-strategic-partnership-to-optimise-biopharma-dealmaking/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/press_release/inpart-and-evaluate-announce-strategic-partnership-to-optimise-biopharma-dealmaking/'
            [ excerpt] => 
            [ intro] => Lyon, France 4th March 2024: In a landmark collaboration, Inpart (previously Inova), a trailblazing software...
            [ intro_full] => Lyon, France 4th March 2024: In a landmark collaboration, Inpart (previously Inova), a trailblazing software provider specialising in biopharma partnering, and Evaluate, a leading insights provider for the biopharma industry and part of Norstella, have officially announced their strategic partnership. This alliance will empower biopharma partnering teams to assess their opportunities quickly and efficiently with decisive data, in the same place.
Inpart&#8217;s flagship product, Deal, enables pharmaceutical companies and biotechs to identify, evaluate, and collaborate seamlessly on strategic partnerships. Paired with Evaluate’s unparalleled AI-enabled intelligence and forecasting solutions, this partnership promises to enhance the impact of critical data by providing direct accessibility for dealmakers when identifying and evaluating opportunities.
Gilles Toulemonde, CEO of Inpart, &#8220;Incorporating Evaluate into our partnering CRM is integrating data into organisation. This is increasing productivity by increasing data quality and integrity. All connected sources are automatically synced and updated to save time and support informed decision-making. Essentially, we&#8217;re empowering our clients to establish trust in their data for the purpose of achieving operational excellence.&#8221;
Chris Kelley, Chief Revenue Officer, Evaluate “This collaboration is strategically designed to foster robust dissemination and collaboration within dealmaking teams by directly embedding Evaluate data in their Inpart workflow – enabling more informed decision-making to help smooth the path of lifesaving therapies from pipeline to patient.”
This strategic partnership underscores the commitment of both companies to advancing the biopharma industry by facilitating stronger collaboration and empowering decision-makers with the tools they need to drive success.
About Inpart:
Inpart is the trusted partner for biopharma and science partnering. The platform provide comprehensive solutions to facilitate, optimize and track interactions in the biopharma, scientific and academic sectors. Inpart’s technology is the preferred choice for more than 6,500 companies including 45/50 of the world&#8217;s leading pharma companies, 25/25 global R&amp;D intensive firms, 25/25 top EU R&amp;D intensive firms and over 200 of the world’s leading universities. Connect, a cutting-edge match making platform, serves as the backbone of a thriving network, uniting over 6,500 industry professionals, academic organizations, biotech companies and investors. Through Connect, Inpart empower users to enhance their visibility, expedite partner discovery, and gain invaluable strategic insights.
Inpart&#8217;s partnering CRM, Deal, is tailored specifically to meet the unique demands of the biopharma sector. Deal streamlines the collaboration and alliance management phases of biopharma partnerships, ensuring efficient and organized operations in executing Biopharma deals.
Discover the suite of products and services: www.inpart.io and follow us on LinkedIn.
About Evaluate
Since 1996, Evaluate, a Norstella company, has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary and industry data into their workflows, tools and processes so they can work more effectively and efficiently.
For more information about Evaluate, visit www.evaluate.com and follow us on LinkedIn and Twitter.
About Norstella
Norstella consists of several prominent pharmaceutical solutions providers—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group—united by a shared mission: to smooth the path to life-saving therapies for patients and providers. Norstella offers comprehensive insights throughout the drug development lifecycle, leveraging unparalleled data, cutting-edge technology, and expert insights and consultancy. For more information, visit Norstella and follow on LinkedIn.
            [ date] => 1709660486
            [ date_modified] => 1709660486
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-300x157.jpg
            [ image_width] => 300
            [ image_height] => 157
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-1024x536.jpg
            [ image_thumb_large_width] => 1024
            [ image_thumb_large_height] => 536
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-768x402.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 402
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-300x157.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 157
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image.jpg
            [ image_thumb_1536x1536_width] => 1200
            [ image_thumb_1536x1536_height] => 628
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image.jpg
            [ image_thumb_2048x2048_width] => 1200
            [ image_thumb_2048x2048_height] => 628
            [ image_title] => Partnership-image
            [ image_alt] => men-shaking-hands-image
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 7054
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-300x157.jpg" alt="men-shaking-hands-image"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/Partnership-image-300x157.jpg" alt="men-shaking-hands-image" width="300" height="157"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_intro_text] => 
            [ cf_button_cta] => 
            [ cf_button_text] => LEARN MORE
            [ cf_form_field] => 
            [ category_id] => 53
            [ category_name] => Press Release
            [ category_slug] => press-release
            [ category_link] => https://www.evaluate.com/category/press-release/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 53
                            [slug] => press-release
                            [name] => Press Release
                            [description] => 
                            [link] => https://www.evaluate.com/category/press-release/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 14
                        )

                )

        )

    [4] => Array
        (
            [ id] => 7048
            [ title] => 2023 in Digital Health: Four Trends Driving Transformation
            [ alias] => 2023-in-digital-health-four-trends-driving-transformation
            [ author_id] => 10
            [ post_type] => post
            [ content] => <p>2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can be attributed to the growing pains of a young-ish market and some to the macroeconomic climate resulting in a scarcity of funding. Whatever the causes, 2023 saw a 36% decline in the number of investors participating in a digital health deal last year and a 37% decline in global venture funding, with levels falling to $22bn. Challenging times.</p>
<p>The latest report from <a href="https://www.galengrowth.com/" target="_blank" rel="noopener">Galen Growth</a>, our <a href="https://www.evaluate.com/thought-leadership/pharma-reports/galen-growth-digital-health-2023-year-end-report">2023 Year End Report,</a> digs into the key themes behind these numbers, and looks at what those themes mean for the industry&#8217;s future. In this post, I’ll share a few highlights around those themes which reveal the drivers of an ecosystem undergoing significant transformation.</p>
<ol>
<li><strong>The evolution in digital health investment:</strong> the digital health landscape as a whole saw huge shifts in 2023. The “sugar high” of Covid, which boosted the whole biopharma industry, crashed back down, with fewer ventures raising funds. A huge 96% of exits in digital health were via M&amp;A, with IPOs being even rarer in this vertical than in biopharma generally – and that was a low bar last year.</li>
<li><strong>A complex environment:</strong> digital health is vast, and it is also central to the transformation of the healthcare ecosystem. But that is not currently translating into funding; only 35% of digital health ventures secured funding in the last 18 months, representing a decline in investor support. That said, there is excitement around <a href="https://www.evaluate.com/thought-leadership/pharma-reports/generative-ai-digital-health">generative AI (GenAI)</a> across the health sphere and it will be an area that investors continue to focus on in 2024 and beyond.</li>
<li><strong>Partnerships and technological integration:</strong> AI, GenAI and ChatGPT are the bright spots in partnerships, with a 3% year-on-year increase in the number of partnerships, taking the proportion of private ventures leveraging AI or GenAI to 39%. Naturally, this has attracted some of the big guns from the technology world – Google, Microsoft and Amazon to name a few &#8211; as they add health-specific AI platforms to their portfolios.</li>
<li><strong>Disrupting clinical research:</strong> 20% of the total funding last year was within research solutions, which, given the focus on R&amp;D efficiencies for biotech and biopharma, is not surprising. Any efforts to reduce costs and to “fail fast” are welcome, and the ability to use digital tools to target drug discovery efforts better and improve clinical trial design is a key focus for many.</li>
</ol>
<p>The report delves into these themes in much more detail, and we investigate the funding challenges, big tech partnerships and the role of clinical evidence in securing financial backing.</p>
<p>While it is a look back at a tough year, the report also provides some fascinating insights into corners of the market that offer promise, and what digital health ventures and investors need to focus on for 2024 and beyond. The data in the report is drawn from <a href="https://www.healthtechalpha.com/" target="_blank" rel="noopener">HealthTech Alpha</a>, our digital health platform, and the team would be delighted to share more details on the unrivalled capabilities of the solution. Meanwhile, <a href="https://www.evaluate.com/thought-leadership/pharma-reports/galen-growth-digital-health-2023-year-end-report">take a look at the full report</a> and I look forward to sharing highlights of our next report very soon.</p>

            [ link] => https://www.evaluate.com/blog/2023-in-digital-health-four-trends-driving-transformation/
            [ link_attributes] => aria-label="Read more about 2023 in Digital Health: Four Trends Driving Transformation" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/blog/2023-in-digital-health-four-trends-driving-transformation/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/blog/2023-in-digital-health-four-trends-driving-transformation/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/blog/2023-in-digital-health-four-trends-driving-transformation/'
            [ excerpt] => 
            [ intro] => 2023 is a year that many in the pharma market will be happy to see the back of, and the digital health...
            [ intro_full] => 2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can be attributed to the growing pains of a young-ish market and some to the macroeconomic climate resulting in a scarcity of funding. Whatever the causes, 2023 saw a 36% decline in the number of investors participating in a digital health deal last year and a 37% decline in global venture funding, with levels falling to $22bn. Challenging times.
The latest report from Galen Growth, our 2023 Year End Report, digs into the key themes behind these numbers, and looks at what those themes mean for the industry&#8217;s future. In this post, I’ll share a few highlights around those themes which reveal the drivers of an ecosystem undergoing significant transformation.

The evolution in digital health investment: the digital health landscape as a whole saw huge shifts in 2023. The “sugar high” of Covid, which boosted the whole biopharma industry, crashed back down, with fewer ventures raising funds. A huge 96% of exits in digital health were via M&amp;A, with IPOs being even rarer in this vertical than in biopharma generally – and that was a low bar last year.
A complex environment: digital health is vast, and it is also central to the transformation of the healthcare ecosystem. But that is not currently translating into funding; only 35% of digital health ventures secured funding in the last 18 months, representing a decline in investor support. That said, there is excitement around generative AI (GenAI) across the health sphere and it will be an area that investors continue to focus on in 2024 and beyond.
Partnerships and technological integration: AI, GenAI and ChatGPT are the bright spots in partnerships, with a 3% year-on-year increase in the number of partnerships, taking the proportion of private ventures leveraging AI or GenAI to 39%. Naturally, this has attracted some of the big guns from the technology world – Google, Microsoft and Amazon to name a few &#8211; as they add health-specific AI platforms to their portfolios.
Disrupting clinical research: 20% of the total funding last year was within research solutions, which, given the focus on R&amp;D efficiencies for biotech and biopharma, is not surprising. Any efforts to reduce costs and to “fail fast” are welcome, and the ability to use digital tools to target drug discovery efforts better and improve clinical trial design is a key focus for many.

The report delves into these themes in much more detail, and we investigate the funding challenges, big tech partnerships and the role of clinical evidence in securing financial backing.
While it is a look back at a tough year, the report also provides some fascinating insights into corners of the market that offer promise, and what digital health ventures and investors need to focus on for 2024 and beyond. The data in the report is drawn from HealthTech Alpha, our digital health platform, and the team would be delighted to share more details on the unrivalled capabilities of the solution. Meanwhile, take a look at the full report and I look forward to sharing highlights of our next report very soon.
            [ date] => 1709565408
            [ date_modified] => 1710948791
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-300x157.jpg
            [ image_width] => 300
            [ image_height] => 157
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-1024x536.jpg
            [ image_thumb_large_width] => 1024
            [ image_thumb_large_height] => 536
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-768x402.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 402
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-300x157.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 157
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA.jpg
            [ image_thumb_1536x1536_width] => 1200
            [ image_thumb_1536x1536_height] => 628
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA.jpg
            [ image_thumb_2048x2048_width] => 1200
            [ image_thumb_2048x2048_height] => 628
            [ image_title] => Featured Image: Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA
            [ image_alt] => Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 7051
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-300x157.jpg" alt="Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2024/03/Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA-300x157.jpg" alt="Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA" width="300" height="157"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_author_image_ID] => 5888
            [ cf_author_image_id] => 5888
            [ cf_author_image_title] => Evaluate-Author-Julien Salaberry
            [ cf_author_image_filename] => Evaluate-Author-Julien-Salaberry.png
            [ cf_author_image_filesize] => 261537
            [ cf_author_image_url] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry.png
            [ cf_author_image_link] => https://www.evaluate.com/blog/revolutionising-pharma-unveiling-the-role-of-digital-health-in-biopharma-giants/attachment/evaluate-author-julien-salaberry/
            [ cf_author_image_alt] => 
            [ cf_author_image_author] => 12
            [ cf_author_image_description] => 
            [ cf_author_image_caption] => 
            [ cf_author_image_name] => evaluate-author-julien-salaberry
            [ cf_author_image_status] => inherit
            [ cf_author_image_uploaded_to] => 5773
            [ cf_author_image_date] => 2024-02-13 19:18:53
            [ cf_author_image_modified] => 2024-02-13 19:19:08
            [ cf_author_image_menu_order] => 0
            [ cf_author_image_mime_type] => image/png
            [ cf_author_image_type] => image
            [ cf_author_image_subtype] => png
            [ cf_author_image_icon] => https://www.evaluate.com/wp-includes/images/media/default.png
            [ cf_author_image_width] => 500
            [ cf_author_image_height] => 500
            [ cf_author_image_sizes] => Array
                (
                    [thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry-150x150.png
                    [thumbnail-width] => 150
                    [thumbnail-height] => 150
                    [medium] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry-300x300.png
                    [medium-width] => 300
                    [medium-height] => 300
                    [medium_large] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry.png
                    [medium_large-width] => 500
                    [medium_large-height] => 500
                    [large] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry.png
                    [large-width] => 500
                    [large-height] => 500
                    [1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry.png
                    [1536x1536-width] => 500
                    [1536x1536-height] => 500
                    [2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/01/Evaluate-Author-Julien-Salaberry.png
                    [2048x2048-width] => 500
                    [2048x2048-height] => 500
                )

            [ cf_author] => Julien De Salaberry
            [ cf_author_title] => CEO & Founder, Galen Growth
            [ cf_author_image_copy] => 
            [ cf_author_copy] => 
            [ cf_author_title_copy] => 
            [ cf_form_field] => 
            [ category_id] => 33
            [ category_name] => Blog
            [ category_slug] => blog
            [ category_link] => https://www.evaluate.com/category/blog/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 33
                            [slug] => blog
                            [name] => Blog
                            [description] => 
                            [link] => https://www.evaluate.com/category/blog/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 56
                        )

                )

        )

    [5] => Array
        (
            [ id] => 6677
            [ title] => Antibody Drug Conjugates Report
            [ alias] => antibody-drug-conjugates-report
            [ author_id] => 12
            [ post_type] => thought-leadership
            [ content] => <div class="report-body">
<div class="clearfix text-formatted mb--lg bg--white p--lg field field--name-body field--type-text-with-summary field--label-hidden field__item">
<p>Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:</p>
<ul>
<li>Pfizer acquired Seagen for $43 billion</li>
<li>AbbVie invested over $10 billion in ImmunoGen</li>
<li>Merck committed $4 billion upfront, with a potential total of $22 billion, for a stake in three of Daiichi Sankyo&#8217;s ADCs</li>
</ul>
<p>Wondering what all the fuss is about and why would-be investors are priced out of the market?</p>
<p>Read our report now for insights on the market landscape, including complexities in the field and key deal drivers. Find out who&#8217;s top of the pile and who&#8217;s poised to make the next move.</p>
<p><a class="turtl-embed" style="width: 340px; max-width: 100%;" title="EVALUATING: Antibody Drug Conjugates" href="https://evaluate.turtl.co/story/evaluating-antibody-drug-conjugates/?teaser=yes" target="_blank" rel="noopener" data-turtl-embed-type="animation" data-turtl-link-text="Click to read" data-turtl-width="340" data-turtl-display-mode="lightbox" data-turtl-animation-mode="hover" data-turtl-color="#1eb1c7" data-turtl-story-id="65c3562bc97b75fd00da508d">Click to read EVALUATING: Antibody Drug Conjugates</a><br />
<!-- Please call embed.js only once per page --><br />
<script async type="text/javascript" data-turtl-script="embed" data-turtl-assets-hostname=https://assets.turtl.co src=https://app-static.turtl.co/embed/turtl.embed.v1.js></script></p>
</div>
</div>

            [ link] => https://www.evaluate.com/thought-leadership/antibody-drug-conjugates-report/
            [ link_attributes] => aria-label="Read more about Antibody Drug Conjugates Report" 
            [ dynamic_popup_link_class__image] => 
            [ dynamic_popup_link_attributes__image] => href='https://www.evaluate.com/thought-leadership/antibody-drug-conjugates-report/'
            [ dynamic_popup_link_class__title] => 
            [ dynamic_popup_link_attributes__title] => href='https://www.evaluate.com/thought-leadership/antibody-drug-conjugates-report/'
            [ dynamic_popup_link_class] => 
            [ dynamic_popup_link_attributes] => href='https://www.evaluate.com/thought-leadership/antibody-drug-conjugates-report/'
            [ excerpt] => 
            [ intro] => Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big...
            [ intro_full] => Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:

Pfizer acquired Seagen for $43 billion
AbbVie invested over $10 billion in ImmunoGen
Merck committed $4 billion upfront, with a potential total of $22 billion, for a stake in three of Daiichi Sankyo&#8217;s ADCs

Wondering what all the fuss is about and why would-be investors are priced out of the market?
Read our report now for insights on the market landscape, including complexities in the field and key deal drivers. Find out who&#8217;s top of the pile and who&#8217;s poised to make the next move.
Click to read EVALUATING: Antibody Drug Conjugates
            [ date] => 1708678853
            [ date_modified] => 1709132527
            [ parent_id] => 0
            [ image] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-300x197.jpg
            [ image_width] => 300
            [ image_height] => 197
            [ image_thumb_large] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d.jpg
            [ image_thumb_large_width] => 900
            [ image_thumb_large_height] => 590
            [ image_thumb_medium_large] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-768x503.jpg
            [ image_thumb_medium_large_width] => 768
            [ image_thumb_medium_large_height] => 503
            [ image_thumb] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-300x197.jpg
            [ image_thumb_width] => 300
            [ image_thumb_height] => 197
            [ image_thumb_thumbnail] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-150x150.jpg
            [ image_thumb_thumbnail_width] => 150
            [ image_thumb_thumbnail_height] => 150
            [ image_thumb_1536x1536] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d.jpg
            [ image_thumb_1536x1536_width] => 900
            [ image_thumb_1536x1536_height] => 590
            [ image_thumb_2048x2048] => https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d.jpg
            [ image_thumb_2048x2048_width] => 900
            [ image_thumb_2048x2048_height] => 590
            [ image_title] => 65c3562bc97b75fd00da508d
            [ image_alt] => Antibody-Drug-Conjugates-Report-featured-image
            [ image_description] => 
            [ image_caption] => 
            [ image_imageid] => 6678
            [ image_attributes_nosize] =>  src="https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-300x197.jpg" alt="Antibody-Drug-Conjugates-Report-featured-image"
            [ image_attributes] =>  src="https://www.evaluate.com/wp-content/uploads/2024/02/65c3562bc97b75fd00da508d-300x197.jpg" alt="Antibody-Drug-Conjugates-Report-featured-image" width="300" height="197"
            [ image_size] => medium
            [ cf_banner_image] => 
            [ cf_intro_text] => 
            [ cf_button_cta] => 
            [ cf_button_text] => LEARN MORE
            [ cf_form_field] => 
            [ category_id] => 42
            [ category_name] => Report/eBook
            [ category_slug] => report-ebook
            [ category_link] => https://www.evaluate.com/category/report-ebook/
            [ categories] => Array
                (
                    [0] => Array
                        (
                            [index] => 0
                            [id] => 42
                            [slug] => report-ebook
                            [name] => Report/eBook
                            [description] => 
                            [link] => https://www.evaluate.com/category/report-ebook/
                            [parent_id] => 0
                            [taxonomy] => category
                            [iscurrent] => 
                            [class_selected] => 
                            [num_posts] => 46
                        )

                )

        )

)
team meeting photo
cell-gene-abstract-image
Biopharma-2022-Whats-Next-featured-image
men-shaking-hands-image
Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA
Antibody-Drug-Conjugates-Report-featured-image
Load More

Webinars

Looking to learn? Our webinar series brings together Evaluate’s experts with industry leaders to talk about the big issues of the day.

News & Events

Check out the latest news from Evaluate and find out where you can come to meet the team.